BioSpace News Archive

endpoint Clinical, the leading global interactive response technology (IRT®) company, announced today the launch of their partnership program, ConnectionPOINT™, the first of its kind in the eClinical technology space.

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced will host a shareholder update call on Wednesday, April 28, 2021 at 4:30 pm ET.

RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Yi Larson to its board of directors effective April 1, 2021. where she worked for over 12 years, followed by Chief Financial Officer at Turning

Cedilla Therapeutics, a venture-backed preclinical biotechnology company developing novel small molecules for cancer and other diseases, today announced the appointment of Chris Bowden, M.D., to its Board of Directors.

Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve diagnostic testing, is announcing today that it has been awarded a contract from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx SM ) Initiative for $8.2 million

enlightenVue, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for expanded claims for vascular diagnostic and therapeutic applications of its SurgiVue™ single-use micro-endoscope platform

Aion Therapeutic Inc. (CSE: AION) (“Aion Therapeutic” or the “Company”) announced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the “Aion Mushroom Preparations” or “Preparations”) showed high efficacy in killing HER2+ breast cancer cells, ER+/PR+ breast cancer cells, and triple-negative breast cancer cells by direct cytotoxicity

Dr. Cindy Basinski and Team at CMB Research, has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure.

QMC HealthID, a wholly owned subsidiary of Quantum Materials Corp, announced that MRS, the Materials Research Society, will feature Quantum Materials among others in the ‘Thought Leadership’ broadcast at the Materials Research Society Virtual Spring Meeting 2021

Battelle is expanding its long-standing commitment to increasing diversity and fostering inclusion within Science, Technology, Engineering and Math (STEM) careers by investing $200,000 over two years to provide students from Bowie State University and Morgan State University research opportunities as they progress from the classroom to employment.